Travere Therapeutics Inc (TVTX): Next-Year EPS Estimate 11681.37%
As of 2026-09-17, Travere Therapeutics Inc (TVTX) has a next-year EPS growth estimate of 11681.37%. Featured in 2 EPS revision reports, most recently on 2026-04-15.
On 2026-09-08, analyst consensus for TVTX's next-year EPS growth shifted from 9888.53% to 11681.37% — a positive change of 1792.84 percentage points. The revised estimate has been sustained across 9 subsequent trading sessions. Current-year growth is projected at 90.59%.
What's Driving This
TVTX shares have risen primarily after analysts sharply upgraded next-year EPS growth estimates on 2026-09-08, from 9888.53% to 11681.37%, a 1792.84 percentage-point increase. The revision follows Q2 2026 earnings-call highlights citing record FILSPARI demand, which plausibly supports the improved outlook. Momentum has continued, with headlines noting a brightening turnaround outlook and increased investor-conference activity.
Generated 2026-09-14 from news as of 2026-09-14
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 11681.37%
- EPS growth this year
- 90.59%
- EPS next quarter (est)
- $0.03
- Last price
- $64.74
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-09-17 | 11681.37% | 90.59% | $0.03 | $64.74 |
| 2026-09-16 | 11681.37% | 90.59% | $0.03 | $63.48 |
| 2026-09-15 | 11681.37% | 90.59% | $0.03 | $62.51 |
| 2026-09-14 | 11681.37% | 90.59% | $0.03 | $65.79 |
| 2026-09-13 | 11681.37% | 90.59% | $0.03 | $66.17 |
| 2026-09-11 | 11681.37% | 90.59% | $0.03 | $66.17 |
| 2026-09-10 | 11681.37% | 90.59% | $0.03 | $67.51 |
| 2026-09-09 | 11681.37% | 90.59% | $0.03 | $66.22 |
| 2026-09-08 | 11681.37% | 90.59% | $0.03 | $66.07 |
| 2026-09-07 | 9888.53% | 88.86% | $0.02 | $65.28 |
| 2026-09-06 | 9888.53% | 88.86% | $0.02 | $65.28 |
| 2026-09-04 | 9888.53% | 88.86% | $0.02 | $65.28 |
| 2026-09-03 | 9888.53% | 88.86% | $0.02 | $66.54 |
| 2026-09-02 | 9888.53% | 88.86% | $0.02 | $67.23 |
| 2026-09-01 | 9888.53% | 88.86% | $0.02 | $65.71 |
| 2026-08-31 | 9888.53% | 88.86% | $0.02 | $66.28 |
| 2026-08-30 | 9888.53% | 88.86% | $0.02 | $65.67 |
| 2026-08-29 | 9888.53% | 88.86% | $0.02 | $65.67 |
| 2026-08-28 | 9888.53% | 88.86% | $0.02 | $65.67 |
| 2026-08-27 | 9888.53% | 88.86% | $0.02 | $67.52 |
| 2026-08-26 | 9888.53% | 88.86% | $0.02 | $67.12 |
| 2026-08-25 | 9888.53% | 88.86% | $0.02 | $67.01 |
| 2026-08-24 | 9888.53% | 88.86% | $0.02 | $65.22 |
| 2026-08-23 | 9888.53% | 88.86% | $0.02 | $65.71 |
| 2026-08-21 | 9888.53% | 88.86% | $0.02 | $65.71 |
| 2026-08-20 | 9888.53% | 88.86% | $0.02 | $64.46 |
| 2026-08-19 | 9888.53% | 88.86% | $0.02 | $65.96 |
| 2026-08-18 | 9888.53% | 88.86% | $0.02 | $63.90 |
| 2026-08-17 | 9888.53% | 88.86% | $0.02 | $63.53 |
| 2026-08-16 | 9888.53% | 88.86% | $0.02 | $62.14 |
Reports Featuring TVTX
Recent News
- Travere Therapeutics Outlook Brightens As Turnaround LoomsInvestor's Business Daily
- Travere Therapeutics to Participate at Upcoming Investor ConferencesBusiness Wire
- Travere Therapeutics to Participate at Upcoming Investor ConferencesBusiness Wire
- Travere Therapeutics Inc (TVTX) (Q2 2026) Earnings Call Highlights: Record FILSPARI Demand and ...GuruFocus.com
- Four Biotech Stocks Near Buy Points As Earnings Season Kicks InInvestor's Business Daily
Screen Performance
Aggregate stats across all 2046 tickers our top-EPS-revision screen has flagged over the past 169 days.
- Median return since detection
- +0.4%
- % of tickers in the green
- 51%
- Median return on winners
- +21.4%
- Large revisions captured
- 1726
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Travere Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-09-17, Travere Therapeutics Inc (TVTX) has a next-year EPS growth estimate of 11681.37%, based on analyst consensus.
When was the latest EPS estimate revision for TVTX?▾
The most recent revision occurred on 2026-09-08, when analysts adjusted the next-year EPS growth estimate from 9888.53% to 11681.37%.
What sector and industry does Travere Therapeutics Inc belong to?▾
Travere Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. TVTX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Travere Therapeutics Inc (TVTX) appears here because it was detected by our daily top-EPS-revision-performer screen.